The survival benefits of adjuvant radiotherapy for malignant meningioma: a retrospective cohort study
Main Article Content
Abstract
Background
Malignant meningiomas (MM) are rare aggressive tumors associated with poor survival outcomes. Due to their rarity, there is limited data on the outcomes and prognostic factors of MM patients, particularly on adjuvant radiotherapy roles in this tumor population. This study aims to investigate the clinical characteristics, prognostic factors, and survival outcomes of MM with focus on survival benefits of adjuvant radiotherapy.
Methods
This retrospective cohort study analyzed 19 MM patients, who were initially subjected to postoperative radiotherapy, at Dr. Kariadi General Hospital, Semarang, from 2013 to 2023. Kaplan-Meier analysis was used to estimate survival rates at 1, 2, and 5 years. Univariate and multivariate Cox regression analyses were performed to identify factors associated with overall survival (OS). Variables with a p-value ≤ 0.25 in univariate analysis were included in the multivariate models.
Results
The median OS was 16 months (95% CI 0.0–40.2), with estimated 1-year, 2-year, and 5-year survival rates of 52.6%, 42.1%, and 15.8%, respectively. Adjuvant radiotherapy (RDT) was associated with a significantly improved OS (p<0.001). However, sex, age, tumor location, and extent of resection did not show a significant association with OS. Cox regression showed that RDT had no statistically significant effect on OS in the multivariate model (HR = 0, 95% CI 0–1.8, p=0.923).
Conclusion
Adjuvant radiotherapy is critical for improving OS in MM patients, and gross-total resection (GTR) alone does not guarantee better long-term outcomes. Further studies with larger cohorts and molecular analysis are necessary to refine treatment strategies for MM.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Seo DO, Song SW, Kim YH, Hong CK, Kim JH. Anaplastic meningioma: Clinical characteristics, prognostic factors and survival outcome. Brain Tumor Res Treat 2022;10:244-54. doi: 10.14791/btrt.2022.0030.
2. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2009-2013. Neuro Oncol 2016;18:v1-v75. doi: 10.1093/neuonc/now207.
3. Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines 2021;9:319. doi: 10.3390/biomedicines9030319.
4. Maier AD, Bartek J, Jr., Eriksson F, et al. Clinical and histopathological predictors of outcome in malignant meningioma. Neurosurg Rev 2020;43:643-53. doi: 10.1007/s10143-019-01093-5.
5. Wang YC, Chuang CC, Wei KC, et al. Long term surgical outcome and prognostic factors of atypical and malignant meningiomas. Sci Rep 2016;6:35743. doi:10.1038/srep35743.
6. Masalha W, Heiland DH, Delev D, et al. Survival and prognostic predictors of anaplastic meningiomas. World Neurosurg 2019;131:e321-e8. doi: 10.1016/j.wneu.2019.07.148
7. Zhao P, Hu M, Zhao M, Ren X, Jiang Z. Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev 2015;38:101-7. doi: 10.1007/s10143-014-0558-2.
8. Garzon-Muvdi T, Yang W, Lim M, Brem H, Huang J. Atypical and anaplastic meningioma: outcomes in a population based study. J Neurooncol 2017;133:321-30. doi: 10.1007/s11060-017-2436-6.
9. Cain SA, Smoll NR, Van Heerden J, Tsui A, Drummond KJ. Atypical and malignant meningiomas: considerations for treatment and efficacy of radiotherapy. J Clin Neurosci 2015;22: 1742-8. doi: 10.1016/j.jocn.2015.03.054.
10. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization grade III meningiomas. J Neurosurg 2010;113:202-9. doi: 10.3171/2010.1.JNS091114.
11. Orton A, Frandsen J, Jensen R, Shrieve DC, Suneja G. Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012. J Neurosurg 2018;128:1684-9. doi: 10.3171/2017.2.JNS162282.
12. Feng S, Li J, Fan F, et al. Prognostic factors and treatment strategies for elderly patients with malignant meningioma: a seer population-based study. Front Oncol 2022;12:913254. doi: 10.3389/fonc.2022.913254.
13. Dwi LP, Supriatna Y, Supriyadi B. Korelasi antara edema otak peritumoral meningioma pada MRI dengan derajat histopatologi (tesis-spesialis). [Correlation between MRI of peritumoral brain edema in meningioma and histopathological grade (specialist thesis)]. Yogyakarta: Universitas Gadjah Mada; 2021. Indonesian.
14. Tian W, Liu J, Zhao K, et al. Analysis of prognostic factors of World Health Organization grade III meningiomas. Front Oncol 2020;10:593073. doi: 10.3389/fonc.2020.593073.
15. Balasubramanian SK, Sharma M, Silva D, et al. Longitudinal experience with WHO grade III (anaplastic) meningiomas at a single institution. J Neurooncol 2017;131:555-63. doi: 10.1007/s11060-016-2321-8.
16. Reddy AK, Ryoo JS, Denyer S, Mcguire LS, Mehta AI. Determining the role of adjuvant radiotherapy in the management of meningioma: a surveillance, epidemiology, and end results analysis. Neurosurg Focus 2019;46:E3. doi: 10.3171/2019.3.Focus1971.
17. Zeng KL, Soliman H, Myrehaug S, et al. Dose-escalated radiation therapy is associated with improved outcomes for high-grade meningioma. Int J Radiat Oncol Biol Phys 2024;118:662-71. doi: 10.1016/j.ijrobp.2023.09.026..
18. Tosefsky K, Rebchuk AD, Wang JZ, et al. Grade 3 meningioma survival and recurrence outcomes in an international multicenter cohort. J Neurosurg 2024;140:393-403. doi: 10.3171/2023.6.JNS23465.
19. Cao J, Yan W, Hong X, Yan H. Epidemiology and survival of non-malignant and malignant meningiomas in middle-aged females, 2004-2018. Front Oncol 2023;13:1157182. doi: 10.3389/fonc.2023.1157182.
20. Pisćević I, Villa A, Milićević M, et al. The influence of adjuvant radiotherapy in atypical and anaplastic meningiomas: a series of 88 patients in a single institution. World Neurosurg 2015;83:987-95. doi: 10.1016/j.wneu.2015.02.021.
21. Cao X, Hao S, Wu Z, et al. Survival rates, prognostic factors and treatment of anaplastic meningiomas. J Clin Neurosci 2015;22:828-33. doi: 10.1016/j.jocn.2014.11.022.
22. Hale AT, Wang L, Strother MK, Chambless LB. Differentiating meningioma grade by imaging features on magnetic resonance imaging. J Clin Neurosci 2018;48:71-5. doi: 10.1016/j.jocn.2017.11.013.
23. Upreti T, Dube S, Pareek V, Sinha N, Shankar J. Meningioma grading via diagnostic imaging: a systematic review and meta-analysis. Neuroradiology 2024;66:1301-10. doi: 10.1007/s00234-024-03404-0.